Tempest Therapeutics Inc (STU:3OS) Stock News, Headlines & Updates
Tempest Therapeutics Inc Stock News from GuruFocus
- 1
Aug 23, 2024
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire • 5:00pm
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
Aug 21, 2024
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Marketwired • 7:00am
Aug 15, 2024
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Marketwired • 7:00am
Aug 08, 2024
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
Marketwired • 4:00pm
Jun 20, 2024
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
Marketwired • 7:00am
Jun 18, 2024
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
Marketwired • 6:00pm
Jun 07, 2024
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00am
May 31, 2024
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
Business Wire • 3:00pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news